
Subgroup analyses from the phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, malaise, and cognition in long COVID patients with more severe baseline symptoms.

Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com

Subgroup analyses from the phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, malaise, and cognition in long COVID patients with more severe baseline symptoms.

Seven experimental DM1 therapies show promise and pitfalls; see latest trial data, a major phase 3 miss, and key 2026 readouts.

The FDA has approved zilganersen (Zanvastro), the first Alexander disease treatment, giving clinicians a disease-modifying option and a clearer framework for counseling patients across the full age and phenotype spectrum.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is emerging muscular dystrophy agents!

The AHA and ASA have replaced their 2016 stroke rehabilitation guideline with expanded, evidence-graded recommendations helping clinicians decide on care settings, comorbidity management, and long-term recovery support.

The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.

Episode 1 features a conversation with Ahmet Hoke, MD, PhD, of Johns Hopkins Medicine, discussing the clinical debate behind keeping animal models for neuropathy research vs switching to induced pluripotent stem cell models.

An indirect comparison found zorevunersen-treated patients with Dravet syndrome showed greater gains in adaptive functioning and behavior than natural history patients.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Aaron Zelikovich, MD. [LISTEN TIME: 18 minutes]

The phase 3 Aspire study of apazunersen did not meet its primary cognition end point or key secondary end point in Angelman syndrome.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

The chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.

A case report documented MOG-IgG antibodies in a mother's breast milk following severe MOGAD, though her breastfed infant's serum tested negative.

A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during glioblastoma resection sharply reduced rapid early tumor regrowth compared with historical rates, setting up a phase 3 randomized trial.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric epilepsy care!

The American Heart Association and American Stroke Association have published an updated, comprehensive guideline for adult stroke rehabilitation, replacing the 2016 version with new and revised recommendations spanning the full recovery continuum.

Brian Lin, PhD, Research Director at the Muscular Dystrophy Association, commented on the first-ever clinical trial framework for Charcot-Marie-Tooth disease, what it means for drug developers, and where the field's biomarker and endpoint evidence still needs to grow.

A coalition of Charcot-Marie Tooth patient groups, clinicians, and pharma companies has published the first consensus framework for designing clinical trials in the disease.

The FDA has cleared Roche's Elecsys pTau217, a blood test that uses a single biomarker to both rule in and rule out amyloid pathology in adults being evaluated for Alzheimer disease, across both primary and specialty care settings.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Huntington disease!

AMO Pharma reached agreement with the FDA, UK MHRA, and Health Canada on the design of a registrational study of AMO-02 for congenital myotonic dystrophy type 1, which will use hospitalization as its primary outcome measure.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Pezhman Roohani, MD. [LISTEN TIME: 17 minutes]

Full results from the phase 3 TEMPO-2 trial, published in Lancet Neurology, showed that flexible-dose tavapadon significantly improved motor symptoms and daily function in people with early Parkinson disease.

David Stamler, MD, Chief Executive Officer of Alterity Therapeutics, discusses the FDA's alignment on the pivotal Phase 3 program for ATH434 in multiple system atrophy and what a successful trial could mean for a disease with no approved disease-modifying therapies.

The cerebrovascular neurosurgeon at University Medical Center New Orleans discussed performing the first Thunderbolt stroke thrombectomy in the United States and what computer-assisted vacuum thrombectomy offers over traditional aspiration.

Oak Hill Bio announced dosing of the first participant in BEACON, a pivotal phase 3 trial evaluating rugonersen, an antisense oligonucleotide originally developed by Roche, for Angelman syndrome.

The new data from ALKIVIA marks the first phase 3 study to show statistically significant, clinically meaningful improvement in immune-mediated necrotizing myopathy, a subtype with no approved therapy.

A phase 3 trial found that solriamfetol significantly improved wakefulness and reduced excessive daytime sleepiness in Chinese patients with obstructive sleep apnea, with a safety profile consistent with prior studies conducted in Western populations.